RxDoctor Payments Data

Teresa Casteel

Nurse Practitioner · Albuquerque, NMNPI 1427183458

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 93.8% of the total across 87 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by Johnson & Johnson at 31.1% of the total. Reporting peaked in 2024 at $887 and has fallen 89.9% since, to $89 in 2025. Among nurse practitioner clinicians in NM with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,686in general payments, 2019–2025

Across 87 payments — averaging $19.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$525
  • AbbVie$318
  • Sanofi$219
  • Takeda Pharmaceuticals U.S.A., Inc.$154
  • Gilead$151
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$88
  • plus $232 from 9 others

What the payments were for

  • Food & beverage$1,58194%
  • Education$1056%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,686 in reported general payments places this provider in the 90th percentile of 624 nurse practitioner providers in New Mexico.

See all nurse practitioner providers in New Mexico

Medicare billing

Part B allowed, 2024
$25,896
Medicare patients
198
Services billed
308

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab24$626,207
LinzessLinaclotide15$7,922
Sucralfate47$3,329
Dexlansoprazole DrDexlansoprazole12$2,961
Budesonide DrBudesonide21$1,774
Famotidine160$1,743
Pantoprazole Sodium125$1,104
Dicyclomine Hcl32$834
Esomeprazole Magnesium31$469
Omeprazole50$336
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl21$335
Ondansetron OdtOndansetron24$194
Fluticasone Propionate18$125

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$525$626,20724 claims
AbbVieLinzess$318$7,92215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 624 nurse practitioner providers in New Mexico.

Other nurse practitioner in Albuquerque

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →